XP Chemistries (XPC) investor relations material

Executive summary

• Transitioned from regulatory milestones to operational commercialization in Q1 2026, focusing on production, certification, and customer validation.

• Initiated scale-up with a leading European contract manufacturer, confirming technical feasibility and product quality for commercial production.

• Deepened collaboration with a European distributor, advancing certification and pilot production of encapsulated capsaicin products.

• Achieved first patent grant in Japan for industrial implementation, strengthening IP position.

Financial highlights

• Net sales for Q1 2026 were 133 TSEK, up from 103 TSEK in Q1 2025.

• Operating result was -3,068 TSEK, compared to -2,123 TSEK in Q1 2025.

• Result before tax was -3,067 TSEK, versus -2,144 TSEK year-over-year.

• Earnings per share for the period was -0.01 SEK, unchanged from the previous year.

• Cash and cash equivalents at March 31, 2026, totaled 12,443 TSEK, up from 3,061 TSEK a year earlier.

Outlook and guidance

• Next development phase for scale-up to be completed by summer 2026, followed by engineering and commercial batches.

• Joint ambition with distributor to negotiate a multi-year distribution agreement after initial evaluations.

• Well positioned to benefit from growing demand for functional feed additives and sustainable solutions.